Figure 1.

The treatments with cisplatin and 5-Aza-2CdR affect the cell viability of the lineages SCC-9, SCC-15, and SCC-25 differently. A. The SCC-9 cells were challenged with two cisplatin concentrations (0.1 and 4.44 µM) and four 5-Aza-2CdR concentrations (0.1, 0.3, 1 and 3 µM). The six groups combined demonstrate the influence of cisplatin concentrations associated with 5-aza-2CdR. B, C. The viability of SCC-15 and SCC-25 cells was assessed only at 0.1 µM concentration of cisplatin and two 5-Aza-2CdR concentrations (0.1 and 0.3 µM), with two combinations between the drugs. No treatment cells were used (control). Cellular viability was assessed by MTT reduction assay and results were expressed as percentage of cell viability, considering the Control group as 100% and presented as mean ± SD of three independent experiments (*P<0.05; ***P<0.001).